Genome-wide association studies（GWASs）have revealed a plethora of putative susceptibility genes for Alzheimer＇s disease（AD）. With the sole exception of the APOE gene, these AD susceptibility genes have not been u...Genome-wide association studies（GWASs）have revealed a plethora of putative susceptibility genes for Alzheimer＇s disease（AD）. With the sole exception of the APOE gene, these AD susceptibility genes have not been unequivocally validated in independent studies. No single novel functional risk genetic variant has been identified. In this review, we evaluate recent GWASs of AD, and discuss their significance, limitations, and challenges in the investigation of the genetic spectrum of AD.展开更多
Chronic kidney disease （CKD） is a major public health problem that affects about 10% of the general population. Current approaches to characterize the category and progression of CKD are normally based on renal hist...Chronic kidney disease （CKD） is a major public health problem that affects about 10% of the general population. Current approaches to characterize the category and progression of CKD are normally based on renal histopathological results and clinical parameters. However, this information is not sufficient to predict CKD progression risk reliably or to guide preventive interventions. Nowadays, the appearance of systems biology has brought forward the concepts of ＂-omics＂ technologies, including genomics, transcriptomics, proteomics, and metabolomics. Systems biology, together with molecular analysis approaches such as microarray analysis, genome-wide association studies （GWAS）, and serial analysis of gene expression （SAGE）, has provided the framework for a comprehensive analysis of renal disease and serves as a starting point for generating novel molecular diagnostic tools for use in nephrology. In particular, analysis of urinary mRNA and protein levels is rapidly evolving as a non-invasive approach for CKD monitoring. All these systems biological molecular approaches are required for application of the concept of ＂personalized medicine＂ to progressive CKD, which will result in tailoring therapy for each patient, in contrast to the ＂one-size-fits-all＂ therapies currently in use.展开更多
基金supported by CHINACANADA Joint Initiative on Alzheimer’s Disease and Related Disorders(81261120571)the National Basic Research Development Program(973 Program)of China(2011CB504104)+6 种基金Scientific Promoting Project of Beijing Institute for Brain Disorders(BIBDPXM2014_014226_000016)Seed Grant of International Alliance of Translational Neuroscience(PXM2014_014226_000006)Key Medical Professional Development Plan of Beijing Municipal Administration of Hospitals(ZYLX201301)the National Science and Technology Major Project for‘‘Major New Drug Innovation and Development’’of the Twelfth 5-year Plan Period of China(2011ZX09307-001-03)the Major Project of the Science and Technology Plan of the Beijing Municipal Science&Technology Commission of China(D111107003111009)the National Key Technology R&D Program in the Eleventh Five-year Plan Period of China(2006BAI02B01)the Key Project of the National Natural Science Foundation of China(30830045)
文摘Genome-wide association studies（GWASs）have revealed a plethora of putative susceptibility genes for Alzheimer＇s disease（AD）. With the sole exception of the APOE gene, these AD susceptibility genes have not been unequivocally validated in independent studies. No single novel functional risk genetic variant has been identified. In this review, we evaluate recent GWASs of AD, and discuss their significance, limitations, and challenges in the investigation of the genetic spectrum of AD.
文摘Chronic kidney disease （CKD） is a major public health problem that affects about 10% of the general population. Current approaches to characterize the category and progression of CKD are normally based on renal histopathological results and clinical parameters. However, this information is not sufficient to predict CKD progression risk reliably or to guide preventive interventions. Nowadays, the appearance of systems biology has brought forward the concepts of ＂-omics＂ technologies, including genomics, transcriptomics, proteomics, and metabolomics. Systems biology, together with molecular analysis approaches such as microarray analysis, genome-wide association studies （GWAS）, and serial analysis of gene expression （SAGE）, has provided the framework for a comprehensive analysis of renal disease and serves as a starting point for generating novel molecular diagnostic tools for use in nephrology. In particular, analysis of urinary mRNA and protein levels is rapidly evolving as a non-invasive approach for CKD monitoring. All these systems biological molecular approaches are required for application of the concept of ＂personalized medicine＂ to progressive CKD, which will result in tailoring therapy for each patient, in contrast to the ＂one-size-fits-all＂ therapies currently in use.
